One-year results of growth hormone treatment of short stature in Prader-Willi syndrome.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

One patient in the treatment group developed pseudotumour cerebri, which resolved after discontinuation of GH; this patient was omitted from further analysis.

Who Took Part

The study group was 17 children.

PubMed indexes the participants as young children and children, both men and women.

To study the effects of exogenous GH on growth and body composition, 17 prepubertal children with Prader-Willi syndrome, with a short projected final height, were randomized to a control group (n = 9) or a treatment group (n = 8).

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Body Height, Growth, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Prader-Willi Syndrome.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Acta paediatrica (Oslo, Norway : 1992). Supplement), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.